Marathonlaufen schützt nicht vor Diabetes
Abstract
Zusammenfassung. Wir berichten über einen 64-jährigen Marathonläufer mit bisher 990 erfolgreich gefinishten Marathons, der fälschlicherweise mit Diabetes mellitus Typ 2 diagnostiziert und therapiert wurde. Unter peroraler Therapie mit Metformin kam es zu keiner Reduktion der Blutzuckerwerte. Nach korrekter Diagnose und Therapie mit Insulin ist der Läufer wieder voll im Training, um bald seinen 1000. Marathon zu laufen. Für Sportler mit Diabetes mellitus Typ 1 ist es wichtig, den Blutzucker vor, während und nach Belastung zu messen und die Insulindosis individuell während eines Wettkampfs, wie etwa einem Marathon, zu reduzieren.
Abstract. We report the case of a 64-year-old marathon runner with 990 successfully finished marathons. He was diagnosed and treated as diabetes mellitus type 2. However, there was no reduction of blood glucose concentration under therapy with metformin. After proper diagnosis and therapy with insulin, the runner is back in training to run his 1000th marathon soon. For athletes with diabetes mellitus type 1, it is important to measure the blood glucose concentration before, during and after exercise, and to reduce the dose of insulin individually during a competition such as a marathon run.
Bibliografie
: Lower prevalence of hypertension, hypercholesterolemia, and diabetes in marathoners. Med Sci Sports Exerc 2009; 41 : 523–529.
: Metabolic and hormonal changes in IDDM during long-distance run. Diabetes Care 1988; 11 : 1–7.
: Type I diabetes and marathon running. Diabetes Care 1993; 16 : 1624–1625.
: Insulin-dependent diabetes mellitus and marathon running. Br J Sports Med 1987; 21 : 51–52.
: Endurance capabilities of triathlon competitors with type 1 diabetes mellitus. Dtsch Med Wochenschr 2009; 134 : 677–682.
: Sweet 452 km – a report on the first type 1 diabetes patient to finish Double Ironman, a 30-hour endurance triathlon race. Croat Med J 2013; 54 : 306–307.
: Blood glucose kinetics and physiological changes in a type 1 diabetic finisher of the Ultraman triathlon: a case study. Eur J Appl Physiol 2017; 117 : 913–919.
: The middle-aged marathon runner. Can Fam Physician 1982; 28 : 941–945.
: Fuel and fluid homeostasis during long-term exercise in healthy subjects and type I diabetic patients. Diabetes Care 1992; 15 : 1736–1741.
: Care of the athlete with type 1 diabetes mellitus: A clinical review. Int J Endocrinol Metab 2016; 14 : e36091.
: Clinical management of the physically active patient with type 1 diabetes. Phys Sportsmed 2011; 39 : 64–65.
: The athlete with type I diabetes: Managing insulin, diet and exercise. Am Fam Physician 1996; 53 : 1611–1617.
: One year follow-up in a group of half-marathon runners with type-1 diabetes treated with insulin analogues. J Sports Med Phys Fitness 2010; 50 : 506–510.
: The adjustment of diet and insulin dose during long-term endurance exercise in type 1 (insulin-dependent) diabetic men. Diabetologia 1988; 31 : 35–40.
: Diabetes in sports. Sports Health 2010; 2 : 29–38.
, : Continuous glucose monitoring in diabetic long distance runners. Int J Sports Med 2005; 26 : 774–780.
: Risks of marathon running and hypoglycaemia in Type 1 diabetes. Diabet Med 2010; 27 : 585–588.
: Sex difference in Double Iron ultra-triathlon performance. Extrem Physiol Med 2013; 2 : 12.
: Participation and performance trends in ’Ultraman Hawaii’ from 1983 to 2012. Extrem Physiol Med 2013; 2 : 25.
